What is Avalyn Pharma?
Avalyn Pharma is a specialized biopharmaceutical enterprise dedicated to the development of inhaled medicines designed to address the limitations of current therapies for rare respiratory diseases. The company's primary focus lies in treating conditions such as Idiopathic Pulmonary Fibrosis and other Interstitial Lung Diseases, which are characterized by severe pulmonary scarring and high mortality risks. By utilizing proprietary inhalation technology, Avalyn aims to minimize systemic exposure while maximizing therapeutic efficacy directly at the site of disease. Its lead candidate, AP01, represents a significant advancement in the delivery of pirfenidone, aiming to improve patient outcomes and safety profiles compared to existing standard-of-care treatments.
How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised a total of $392.5M across 7 funding rounds:
Private Equity
$2.2M
Unspecified
$1.2M
Private Equity
$16.6M
Series A
$62M
Series B
$35.5M
Series C
$175M
Series D
$100M
Private Equity (2011): $2.2M, investors not publicly disclosed
Unspecified (2012): $1.2M, investors not publicly disclosed
Private Equity (2017): $16.6M, investors not publicly disclosed
Series A (2017): $62M featuring F-Prime Capital Partners, Edmond de Rothschild Investment Partners, TPG Biotech, RiverVest Venture Partners, and Novo AS
Series B (2020): $35.5M backed by F-Prime Capital, PIVOTAL BIOVENTURE PARTNERS LLC, RiverVest Venture Partners, Novo Holdings, Norwest Venture Partners, and TPG Biotech
Series C (2023): $175M with participation from Rock Springs Capital, SR One, Eventide Asset Management, Wellington Management, and Vida Ventures
Series D (2025): $100M led by Vida Ventures, TPG Biotech, Catalio Capital Management, SR One, Norwest Venture Partners, Eventide Asset Management, RiverVest Venture Partners, Wellington Management, Novo Holdings, Suvretta Capital Management, F-Prime Capital, Pivotal Healthcare Partners, and Xontogeny
Key Investors in Avalyn Pharma
Vida Ventures
Vida Ventures is a next-generation life sciences investment firm founded by scientists and entrepreneurs, managing approximately $1.7 billion to advance transformative biomedical innovations.
TPG Biotech
TPG Biotech is the growth equity and venture investment platform of TPG, focusing on pharmaceutical discovery, medical technology, and life sciences innovation.
Catalio Capital Management
Catalio Capital Management is a New York-based firm specializing in innovative healthcare investing, managing $2 billion in assets with a focus on breakthrough biomedical technologies.
What's next for Avalyn Pharma?
With the successful closure of this major strategic investment, Avalyn Pharma is well-positioned to advance its clinical-stage programs through late-phase trials. The strategic allocation of these funds will likely prioritize the progression of AP01, ensuring the company maintains its competitive edge in the respiratory therapeutics market. As the firm moves forward, the focus will remain on achieving clinical proof-of-concept and navigating the regulatory landscape to bring transformative inhaled treatments to patients with high unmet medical needs. The continued participation of institutional heavyweights suggests a strong roadmap toward potential commercialization or further strategic partnerships in the global biotech sector.
See full Avalyn Pharma company page
